Manas AI, a full-stack, AI-driven company focused on discovering and advancing next generation medicines, launched today. By leveraging its proprietary AI-driven platform, its partnership with Microsoft, and a world-class team of scientists across diverse disciplines, Manas AI is uniquely positioned to disrupt the traditional model of therapeutic discovery. The company aims to significantly accelerate the process of screening, identifying, and advancing transformative medicines for cancer, autoimmune disease, and rare conditions — including some previously considered unreachable.
Co-founded by Dr. Siddhartha Mukherjee, a pioneering oncologist, researcher, and author, and Reid Hoffman, renowned entrepreneur and investor, Manas AI integrates generative computational chemistry, advanced molecular docking, and cutting-edge biology to create a full-stack therapeutic development pipeline — from target identification to clinical trials. Manas will use Microsoft’s cloud computing platform, Microsoft Azure, as well as Microsoft’s deep domain knowledge in AI to develop novel medicines.
Dr. Siddhartha Mukherjee stated: “Our mission is simple yet profound: to transform how we discover and develop life-saving medicines. Through the power of AI and our world-class team, we believe we can drastically reduce the time and cost it takes to bring game-changing new treatments to patients. I am particularly excited about the novel models for generative chemistry that Manas is developing. If these generative models work, we aspire to replace conventional experimental methods to create medicines.”
Disrupting Medical Discovery with AI and Compute Power
Manas AI’s proprietary approach builds on several distinctive foundations. First, proprietary AI filters and libraries: Manas AI generates bespoke chemical libraries and utilizes advanced AI filters to identify high-potential therapeutic candidates with paradigm-shifting speed and accuracy. Second, massive scale compute: through the Microsoft collaboration, Manas AI will build on top of the Azure cloud computing infrastructure, enabling molecular docking at speeds 100x faster than traditional systems. Third, Project Cosmos: the company’s ambitious AI-driven initiative aims to map the fundamental “rules” of drug binding, further accelerating the discovery of novel chemical entities.
Peter Lee from Microsoft remarked: “Amidst all the hype in AI-powered drug discovery today, Manas AI is poised to make truly practical, game-changing advances. It’s especially exciting to integrate world-class AI capabilities with groundbreaking chemistry, biology, and wet-lab expertise as we aim to re-shape the future of medicine. Microsoft is proud to partner with Manas to help realize this critically important mission.”
Global Vision for Impact
With an initial focus on oncology, Manas AI is developing treatments for aggressive cancers such as triple-negative breast cancer, prostate cancer, and lymphoma. Eventually, the company also intends to target other important global diseases.
World-Class Scientific Team
Manas AI has assembled an interdisciplinary team of leaders in novel medicine discovery spanning AI, computational chemistry, biology, and clinical research. The team includes five members of the National Academy of Sciences, four members of the National Academy of Medicine, and two recipients of the Breakthrough Prize in Life Sciences.
Dr. Mukherjee elaborated: “Our interdisciplinary team is uniquely equipped to tackle the most complex challenges in drug discovery. By combining expertise in AI and biology with best-in-class preclinical models, we can accelerate the process of discovering life-saving medicines that were once out of reach.”
Funding and Investor Backing
Manas AI raised $24.6 million in seed funding to accelerate its AI-driven drug discovery programs. The financing was led by General Catalyst with participation from Greylock and other strategic life sciences and technology investors.
Ken Frazier, chairman of health assurance initiatives at General Catalyst and former Merck chairman and CEO, stated: “Manas AI has the potential to compress the timeline to discovery of effective drug candidates while increasing the likelihood of success in clinical trials. This is a unique opportunity to dramatically change the drug discovery landscape and make a positive impact on billions of people around the world.”
Reid Hoffman, co-founder and investor, commented: “AI will have a lasting and positive impact on humanity, and for years I have been focused on helping realize the potential of this technology. It’s my honor to partner with Sid to build a company focused on using AI to transform drug discovery. Manas AI is breaking down barriers that have slowed medical innovation for decades, which will lead to exponential positive impact in our ability to treat human disease.”
About Manas AI
Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.